ATLANTA and RARITAN, N.J., Dec. 11, 2017 /PRNewswire/ — Janssen Research & Development, LLC today announced new data from the Phase 1b PAVO clinical study, which demonstrated that the subcutaneous delivery of DARZALEX® (daratumumab) had a manageable safety profile and a 12 percent rat…
